优化治疗类风湿关节炎的低剂量甲氨蝶呤：综述。
Optimising low-dose methotrexate for rheumatoid arthritis-A review.
机构信息
Discipline of Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.
Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
出版信息
Br J Clin Pharmacol. 2019 Oct;85(10):2228-2234. doi: 10.1111/bcp.14057. Epub 2019 Aug 9.
Abstract
Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.
摘要
甲氨蝶呤低剂量（5-25 毫克/周）是类风湿关节炎的一线治疗药物。然而，在反应中存在个体间和个体内的差异，其与活性多聚谷氨酸代谢物浓度的差异有关，而这些差异与临床疗效和毒性有关。在不同人群、疾病状态和方案中，处方仍然存在异质性。这篇综述检查了目前在类风湿关节炎背景下口服甲氨蝶呤的剂量反应知识，以及这如何帮助确定剂量方案。
相似文献
1
Optimising low-dose methotrexate for rheumatoid arthritis-A review.
Br J Clin Pharmacol. 2019 Oct;85(10):2228-2234. doi: 10.1111/bcp.14057. Epub 2019 Aug 9.
2
Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.
Clin Pharmacokinet. 1996 Mar;30(3):194-210. doi: 10.2165/00003088-199630030-00002.
3
Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.
Rheumatology (Oxford). 2010 Dec;49(12):2337-45. doi: 10.1093/rheumatology/keq216. Epub 2010 Aug 16.
4
Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.
Arthritis Rheum. 2009 Aug;60(8):2248-56. doi: 10.1002/art.24653.
5
Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.
Ann Rheum Dis. 2014 Aug;73(8):1549-51. doi: 10.1136/annrheumdis-2014-205228. Epub 2014 Apr 12.
6
Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.
Clin Ther. 2018 Feb;40(2):309-319. doi: 10.1016/j.clinthera.2018.01.002.
7
Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.
Arthritis Rheum. 2010 Feb;62(2):359-68. doi: 10.1002/art.27201.
8
High Methotrexate Triglutamate Level Is an Independent Predictor of Adverse Effects in Asian Indian Rheumatoid Arthritis Patients-A Preliminary Study.
Ther Drug Monit. 2017 Apr;39(2):157-163. doi: 10.1097/FTD.0000000000000375.
9
Benefit and risk of methotrexate treatment in rheumatoid arthritis.
Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S83-94.
10
Measuring methotrexate polyglutamates.
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S24-6. Epub 2010 Oct 28.
引用本文的文献
1
A Case of Erythrodermic Psoriasis Successfully Treated With Ixekizumab Combined With Low-Dose Methotrexate to Ensure Sustained Clearance: A Case Report.
Case Rep Dermatol Med. 2025 May 29;2025:8810497. doi: 10.1155/crdm/8810497. eCollection 2025.
2
Differential response of tissue engineered skeletal muscle from rheumatoid arthritis patients and healthy controls.
Commun Biol. 2025 Apr 9;8(1):583. doi: 10.1038/s42003-025-07970-8.
3
Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity.
Front Pharmacol. 2025 Jan 9;15:1397995. doi: 10.3389/fphar.2024.1397995. eCollection 2024.
4
Translational Research in Oral Lichen Planus: From Laboratory Discoveries to Clinical Applications.
Cureus. 2024 Oct 14;16(10):e71462. doi: 10.7759/cureus.71462. eCollection 2024 Oct.
5
A reconfigurable integrated smart device for real-time monitoring and synergistic treatment of rheumatoid arthritis.
Sci Adv. 2024 May 3;10(18):eadj0604. doi: 10.1126/sciadv.adj0604. Epub 2024 May 1.
6
Effect of vitamin B12 on methotrexate-induced cardiotoxicity in rats.
Iran J Basic Med Sci. 2024;27(6):733-739. doi: 10.22038/IJBMS.2024.74161.16120.
7
An acute herb-drug interaction of Magnoliae Officinalis Cortex with methotrexate via inhibiting multidrug resistance-associated protein 2.
J Food Drug Anal. 2024 Mar 15;32(1):103-111. doi: 10.38212/2224-6614.3495.
8
Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes.
BMC Rheumatol. 2024 Mar 5;8(1):11. doi: 10.1186/s41927-024-00381-y.
9
L-methionine protects against nephrotoxicity induced by methotrexate through modulation of redox status and inflammation.
Redox Rep. 2023 Dec;28(1):2270886. doi: 10.1080/13510002.2023.2270886. Epub 2023 Nov 6.
10
Oral Versus Subcutaneous Methotrexate in Immune-Mediated Inflammatory Disorders: an Update of the Current Literature.
Curr Rheumatol Rep. 2023 Dec;25(12):276-284. doi: 10.1007/s11926-023-01116-7. Epub 2023 Sep 28.
本文引用的文献
1
Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study.
Pharmgenomics Pers Med. 2018 Nov 12;11:205-210. doi: 10.2147/PGPM.S170557. eCollection 2018.
2
Diagnosis and Management of Rheumatoid Arthritis: A Review.
JAMA. 2018 Oct 2;320(13):1360-1372. doi: 10.1001/jama.2018.13103.
3
A Rapidly Fatal Case of Low-Dose Methotrexate Toxicity.
Case Rep Med. 2018 Jun 13;2018:9056086. doi: 10.1155/2018/9056086. eCollection 2018.
4
Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis.
Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):885-893. doi: 10.1002/pds.4555. Epub 2018 May 24.
5
Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study.
Arthritis Res Ther. 2018 Mar 20;20(1):50. doi: 10.1186/s13075-018-1544-9.
6
Dissect new mechanistic insights for geniposide efficacy on the hepatoprotection using multiomics approach.
Oncotarget. 2017 Oct 19;8(65):108760-108770. doi: 10.18632/oncotarget.21897. eCollection 2017 Dec 12.
7
Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
Arthritis Res Ther. 2017 Nov 22;19(1):258. doi: 10.1186/s13075-017-1468-9.
8
Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort.
Ann Rheum Dis. 2017 Dec;76(12):2054-2060. doi: 10.1136/annrheumdis-2017-211268. Epub 2017 Sep 2.
9
When less is more - efficacy with less toxicity at the ED50.
Br J Clin Pharmacol. 2017 Jul;83(7):1365-1368. doi: 10.1111/bcp.13281. Epub 2017 Apr 6.
10
Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
Sci Rep. 2017 Mar 7;7:44015. doi: 10.1038/srep44015.
Zotero 插件